What is the initial dose of glargine (insulin glargine) for a patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Initial Dosing of Insulin Glargine

The recommended initial dose of insulin glargine is 10 units per day or 0.1-0.2 units/kg of body weight for insulin-naive patients. 1

Dosing Guidelines Based on Patient Type

For Type 2 Diabetes Patients

  • Start with 10 units per day or 0.1-0.2 units/kg of body weight 1, 2
  • Continue oral antidiabetic medications, particularly metformin 1
  • Administer once daily, typically at bedtime, but can be given at any time of day 1, 3
  • Individuals with type 2 diabetes generally require higher daily doses (up to 1 unit/kg) due to insulin resistance 4

For Type 1 Diabetes Patients

  • Initial dose typically ranges from 0.4 to 1.0 units/kg/day 4
  • Generally, 50% of the total daily insulin requirement should be basal insulin and 50% as prandial insulin 4
  • A typical starting dose in metabolically stable patients is 0.5 units/kg/day, with half as basal insulin 4

For Elderly Patients

  • Use lower initial doses (0.1 units/kg/day) to minimize hypoglycemia risk 1
  • Consider simplified insulin regimens as outlined in the Standards of Care for older adults 4

Titration Protocol

After initiating insulin glargine, adjust the dose as follows:

  • Increase dose by 2 units once or twice weekly until fasting glucose target is reached 1
  • If 50% of fasting glucose values are above target, increase by 2 units 4
  • If more than 2 fasting glucose values per week are below 80 mg/dL (4.4 mmol/L), decrease dose by 2 units 4, 1
  • Target fasting glucose range: 90-150 mg/dL (5.0-8.3 mmol/L) for older adults 4; 80-130 mg/dL for general population 2

Special Considerations

Overbasalization

  • Avoid continuing to escalate basal insulin dose without meaningful reduction in fasting glucose 2
  • If basal insulin has been titrated to an acceptable fasting glucose level (or if dose exceeds 0.5 units/kg/day) and A1C remains above target, consider advancing to combination injectable therapy 4

Timing of Administration

  • Insulin glargine can be administered at any time of day, provided it's given at the same time each day 1, 3
  • In some cases, splitting the dose to twice daily may be beneficial for patients experiencing hypoglycemia despite dose titration 5

Concentrated Formulations

  • U-300 glargine and U-200 degludec are concentrated formulations that allow higher doses per volume 4
  • These may be more comfortable for patients requiring large doses of insulin 4

Common Pitfalls to Avoid

  • Delayed titration: Timely dose adjustment is critical for achieving glycemic targets 1
  • Ignoring hypoglycemia: Reduce dose if fasting glucose falls below target or nocturnal hypoglycemia occurs 1
  • Premature discontinuation of oral agents: Metformin should generally be continued when initiating basal insulin 1
  • Mixing with other insulins: Insulin glargine should not be mixed with other insulin formulations due to its low pH 1, 3

By following these evidence-based guidelines for insulin glargine initiation, clinicians can effectively manage hyperglycemia while minimizing the risk of adverse events such as hypoglycemia.

References

Guideline

Initiating Long-Acting Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Insulin Glargine: a review 8 years after its introduction.

Expert opinion on pharmacotherapy, 2009

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Benefits of twice-daily injection with insulin glargine: a case report and review of the literature.

Tennessee medicine : journal of the Tennessee Medical Association, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.